Xu et al., 2018 - Google Patents
Two tandem repeats of mHSP70407–426 enhance therapeutic antitumor effects of a recombined vascular endothelial growth factor (VEGF) protein vaccineXu et al., 2018
View PDF- Document ID
- 12161929923024770225
- Author
- Xu M
- Zhang Y
- Dong W
- Jiang L
- Zhang J
- Yu P
- Xie S
- Zhou L
- Publication year
- Publication venue
- Life sciences
External Links
Snippet
Aims Active immunization with human vascular endothelial growth factor (hVEGF) vaccines provides a therapeutic option instead of bevacizumab therapy. However, the immunity to self- molecule is difficult to elicit due to immune tolerance. A bioactive peptide of two tandem …
- 229960005486 vaccines 0 title abstract description 65
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10071147B2 (en) | Method for enhancing immune response in the treatment of infectious and malignant diseases | |
| JP7685737B2 (en) | Factor 1 and factor 2 proteins and their inhibitors for use in the treatment or prevention of disease - Patents.com | |
| Hartman et al. | Increasing vaccine potency through exosome antigen targeting | |
| JP6616189B2 (en) | A novel anti-transferrin receptor antibody that crosses the blood-brain barrier | |
| ES2675825T3 (en) | Tumor vaccination involving an immune response against the CLDN18.2 protein itself | |
| CN108840923B (en) | Polypeptide targeting PD-L1 and application thereof | |
| JP6941321B2 (en) | Conjugate vaccine that targets in vivo proteins that cause disease | |
| CN113646008A (en) | pHLIP® Peptide-Mediated Cell Surface Epitope Binding | |
| JP7312412B2 (en) | Modified orthopoxvirus vector | |
| JP2017518958A (en) | Antibodies against immunogenic glycopeptides, compositions containing them, and uses thereof | |
| US20170260246A1 (en) | Carcinoma homing peptide (chp), its analogs, and methods of using | |
| RU2020129180A (en) | THERAPEUTIC BIOPREPARATION FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | |
| JP2019013229A (en) | CyaA-BASED CHIMERIC PROTEINS COMPRISING HETEROLOGOUS POLYPEPTIDE AND THEIR USES IN INDUCTION OF IMMUNE RESPONSES | |
| Yang et al. | Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer | |
| CN106279435A (en) | The anti-tumor vaccine of targeting VEGF Yu mucin1, encoding gene, expression vector, expression engineering bacteria and application | |
| Xu et al. | Two tandem repeats of mHSP70407–426 enhance therapeutic antitumor effects of a recombined vascular endothelial growth factor (VEGF) protein vaccine | |
| EP3836951A1 (en) | Peptides and compositions for targeted treatment and imaging | |
| JP2021506320A (en) | Enzyme-mediated depletion of adenosine and / or methylthioadenosine | |
| Zhang et al. | Soluble production and function of vascular endothelial growth factor/basic fibroblast growth factor complex peptide | |
| EP3231441A1 (en) | Novel protein structure produced by effective antibody used for immunization | |
| US20230346969A1 (en) | Intermediate for preparing antibody-drug conjugate (adc), preparation method therefor, and use thereof | |
| CN105985447A (en) | Albumin-bound tumor necrosis factor-related apoptosis-inducing ligand variant and preparation method and application thereof | |
| Zhang et al. | RETRACTED: The Design, Characterizations, and Tumor Angiogenesis Inhibition of a Multi-Epitope Peptibody With bFGF/VEGFA | |
| ES2737723T3 (en) | Compositions comprising IL-31 and uses thereof | |
| JP2020502273A (en) | Stable polymeric novel recombinant protein UK114 for use in the treatment, diagnosis and prevention of malignant solid and systemic tumors |